Skip to content



Company Profile

Arena is a biopharmaceutical company focused on discovering and developing novel, small molecule drugs. We are currently directing our activities and resources primarily on:

Stock Quote

Copyright Nasdaq. Minimum 15 minutes delayed.

Events & Presentations
Annual Report and Proxy Statement
Date Title and Summary
Toggle Summary Arena Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2018 Financial Results
- Initiated ADVANCE Phase 3 Program for Ralinepag in Pulmonary Arterial Hypertension (PAH) - Completed Enrollment for Olorinab Study for Pain Associated with Crohn's Disease; Data in Q3:18 - Submitted Etrasimod Meeting Request to the FDA for Ulcerative Colitis (UC) SAN DIEGO , Aug.
Toggle Summary Arena Pharmaceuticals to Release Second Quarter 2018 Financial Results and Provide Corporate Update on Monday, August 6
SAN DIEGO , July 30, 2018 /PRNewswire/ -- Arena Pharmaceuticals, Inc. (Nasdaq: ARNA) today announced that the Company will release its second quarter 2018 financial results and provide a corporate update on Monday, August 6, 2018 , after the close of the U.S.